

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-29. (canceled).

30. (new) A method for identifying compounds which interact with the kinase domain of a modified receptor tyrosine kinase (RTK) polypeptide, comprising the steps of:

- (a) expressing in a host cell an isolated DNA sequence or variant thereof which encodes a modified RTK gene construct, wherein said RTK gene construct contains an RTK kinase domain α helix D linked to RTK kinase domain α helix E by a truncated RTK kinase insert domain (KID), said host cell capable of producing a modified RTK polypeptide that retains kinase activity and which forms crystals suitable for x-ray crystallography, wherein the modified RTK polypeptide is vascular endothelial growth factor receptor-2 (VEGFR-2);
- (b) exposing said modified RTK polypeptide to said compound; and
- (c) evaluating the interaction between the modified RTK polypeptide and said compound.

31. (new) A method for identifying compounds which interact with the kinase domain of a modified receptor tyrosine kinase (RTK) polypeptide, comprising the steps of:

- (a) expressing in a host cell an isolated DNA sequence or variant thereof which encodes a modified RTK gene construct, wherein said RTK gene construct contains an RTK kinase domain α helix D linked to RTK kinase domain α helix E by a truncated RTK kinase insert domain (KID), said host cell capable of producing a modified RTK polypeptide that retains kinase activity and which forms crystals suitable for x-ray crystallography, wherein the modified RTK polypeptide comprises the VEGFR2 Δ 50 polypeptide of SEQ ID NO: 5;
- (b) exposing said modified RTK polypeptide to said compound; and
- (c) evaluating the interaction between the modified RTK polypeptide and said compound.